1. Kevan Polkinghorne Aarti Gulyani Stephen McDonald Kylie Hurst CHAPTER 5 HAEMODIALYSIS (including home haemodialysis) 2012 Annual Report—35th Edition ANZDATA Registry Annual Report 2012

2. Figure 5.1 Stock and Flow of Haemodialysis Patients 2007 - 2011 20072008200920102011 Australia Patients new to HD20202153207020362141 First Dialysis Treatment17291792171717221811 Previous Dialysis (PD)268321314279297 Failed Transplant2340393533 Transplanted405535495550517 Deaths11631201122611491220 Never Transplanted10841138115010811145 Previous Transplant7963766875 Transfer to PD436488428367371 Patients Dialysing (HD) at 31 December75937924825185958929 Patients Dialysing (HD) at Home at 31 December949951977974972 % of all Home Dialysis (HD and PD) Patients31%30%31%32% New Zealand Patients new to HD380394429398403 First Dialysis Treatment311320360333313 Previous Dialysis (PD)5766595880 Failed Transplant128107 Transplanted6069614762 Deaths177236205 229 Never Transplanted167219192182219 Previous Transplant1017132310 Transfer to PD146158118162123 Patients Dialysing (HD) at 31 December13251343148115531591 Patients Dialysing (HD) at Home at 31 December327331378424433 % of all Home Dialysis (HD and PD) Patients31%30%32%34%36% ANZDATA Registry Annual Report 2012

3. Figure 5.2 ANZDATA Registry Annual Report 2012

4. Figure 5.3 Stock and Flow of Haemodialysis Patients Australia 2007 - 2011 Number (%) Age Groups 20072008200920102011 New Patients * 00-14 years9 (0%)13 (1%)9 (0%)14 (1%)17 (1%) 15-24 years45 (2%)42 (2%)45 (2%)43 (2%) 25-34 years94 (5%)101 (5%)88 (4%)78 (4%)81 (4%) 35-44 years187 (9%)173 (8%)178 (9%)172 (8%)196 (9%) 45-54 years315 (16%)345 (16%)313 (15%)314 (15%)323 (15%) 55-64 years437 (22%)448 (21%)447 (22%)441 (22%)478 (22%) 65-74 years484 (24%)542 (25%)516 (25%)482 (24%)522 (24%) 75-84 years405 (20%)432 (20%)416 (20%)408 (20%)418 (20%) >=85 years44 (2%)57 (3%)58 (3%)84 (4%)63 (3%) Total2020 (100%)2153 (100%)2070 (100%)2036 (100%)2141 (100%) Patients Dialysing 00-14 years5 (0%)10 (0%)9 (0%)10 (0%)12 (0%) 15-24 years98 (1%)88 (1%)91 (1%)99 (1%)108 (1%) 25-34 years305 (4%)290 (4%)292 (4%)291 (3%)285 (3%) 35-44 years737 (10%)693 (9%)695 (8%)694 (8%)725 (8%) 45-54 years1211 (16%)1275 (16%)1316 (16%)1314 (15%)1335 (15%) 55-64 years1619 (21%)1721 (22%)1781 (22%)1861 (22%)1931 (22%) 65-74 years1803 (24%)1895 (24%)1985 (24%)2064 (24%)2133 (24%) 75-84 years1602 (21%)1685 (21%)1772 (21%)1871 (22%)1978 (22%) >=85 years213 (3%)267 (3%)310 (4%)391 (5%)422 (5%) Total7593 (100%)7924 (100%)8251 (100%)8595 (100%)8929 (100%) Primary Renal Disease * Glomerulonephritis484 (24%)463 (22%)506 (24%)426 (21%)477 (22%) Analgesic Nephropathy 46 (2%) 40 (2%)38 (2%)27 (1%) Hypertension319 (16%)322 (15%)288 (14%)285 (14%)326 (15%) Polycystic Disease127 (6%)125 (6%)123 (6%)136 (7%)122 (6%) Reflux Nephropathy56 (3%)59 (3%)61 (3%)43 (2%)49 (2%) Diabetic Nephropathy642 (32%)748 (35%)686 (33%)741 (36%)774 (36%) Miscellaneous215 (11%)233 (11%)231 (11%)250 (12%)252 (12%) Uncertain131 (6%)157 (7%)135 (7%)117 (6%)114 (5%) Total2020 (100%)2153 (100%)2070 (100%)2036 (100%)2141 (100%) * New patients receiving first haemodialysis treatment ANZDATA Registry Annual Report 2012

5. Figure 5.4 ANZDATA Registry Annual Report 2012

6. Figure 5.5 Stock and Flow of Haemodialysis Patients New Zealand 2007 - 2011 Number (%) Age Groups20072008200920102011 New Patients * 00-14 years3 (1%)5 (1%)2 (0%)1 (0%) 15-24 years21 (6%)19 (5%)10 (2%)12 (3%)15 (4%) 25-34 years17 (4%)15 (4%)24 (6%)12 (3%)19 (5%) 35-44 years45 (12%)34 (9%)54 (13%)40 (10%)44 (11%) 45-54 years63 (17%)84 (21%)89 (21%)97 (24%)78 (19%) 55-64 years100 (26%)117 (30%)103 (24%)112 (28%)105 (26%) 65-74 years88 (23%)89 (23%)93 (22%)82 (21%)100 (25%) 75-84 years39 (10%)30 (8%)51 (12%)39 (10%)38 (9%) >=85 years4 (1%)1 (0%)3 (1%) Total380 (100%)394 (100%)429 (100%)398 (100%)403 (100%) Patients Dialysing 00-14 years3 (0%) 4 (0%)1 (0%) 15-24 years39 (3%)38 (3%)41 (3%)45 (3%)40 (3%) 25-34 years80 (6%)76 (6%)90 (6%)89 (6%)90 (6%) 35-44 years160 (12%)149 (11%)162 (11%)165 (11%)172 (11%) 45-54 years261 (20%)275 (20%)309 (21%)329 (21%)331 (21%) 55-64 years364 (27%)373 (28%)403 (27%)431 (28%)448 (28%) 65-74 years297 (22%)293 (22%)316 (21%)323 (21%)343 (22%) 75-84 years108 (8%)126 (9%)146 (10%)152 (10%)147 (9%) >=85 years13 (1%)10 (1%)11 (1%)15 (1%)19 (1%) Total1325 (100%)1343 (100%)1481 (100%)1553 (100%)1591 (100%) Primary Renal Disease * Glomerulonephritis89 (23%)72 (18%)97 (23%)89 (22%)98 (24%) Analgesic Nephropathy3 (1%)1 (0%) 2 (0%) Hypertension43 (11%)33 (8%)43 (10%)38 (10%)41 (10%) Polycystic Disease15 (4%)14 (4%)18 (4%)13 (3%)19 (5%) Reflux Nephropathy8 (2%)9 (2%)3 (1%)6 (2%)8 (2%) Diabetic Nephropathy163 (43%)204 (52%)212 (49%)205 (52%)173 (43%) Miscellaneous47 (12%)46 (12%)41 (10%)36 (9%)39 (10%) Uncertain12 (3%)15 (4%)14 (3%)11 (3%)23 (6%) Total380 (100%)394 (100%)429 (100%)398 (100%)403 (100%) * New patients receiving first haemodialysis treatment ANZDATA Registry Annual Report 2012

7. Figure 5.6 ANZDATA Registry Annual Report 2012

8. Figure 5.7 ANZDATA Registry Annual Report 2012

9. Figure 5.8 ANZDATA Registry Annual Report 2012

10. Figure 5.9 ANZDATA Registry Annual Report 2012

11. Figure 5.10 Blood Flow Rates (mls/minute) 2007 - 2011 Country No. Pts *CVV HD excluded NR** Mls/Minute <200200-249250-299300-349350-399>400 Aust December 2011 884408528270124251631867274 December 2010 858131139296122649831721316 December 2009 82501047293120847421629331 December 2008 79230152350128243401590309 December 2007 75892236344140040361479294 NZ December 2011 158803410733090622219 December 2010 15530059639376825932 December 2009 14801049436868030034 December 2008 134300610142655323225 December 2007 13250068738154527828 ANZDATA Registry Annual Report 2012

12. Figure 5.11 Blood Flow Rate by Type of Access December 2011 Blood Flow Rate AustraliaNew Zealand AVFAVGCVC*NR**AVFAVGCVCNR** <20010 (.1%)1 (.1%)17 (1.5%)03 (.3%)01 (.3%)0 200-249174 (2.5%)34 (4.9%)62 (5.3%)064 (5.5%)3 (3.8%)40 (11.5%)0 250-299840 (12%)98 (14.2%)302 (25.9%)2 (2.2%)190 (16.4%)25 (31.3%)114 (32.9%)1 (33.3%) 300-3494051 (58%)421 (61.1%)684 (58.7%)7 (7.9%)671 (57.8%)49 (61.3%)186 (53.6%)0 350-3991653 (23.7%)119 (17.3%)93 (8%)2 (2.2%)213 (18.3%)3 (3.8%)6 (1.7%)0 >=400253 (3.6%)15 (2.2%)5 (.4%)1 (1.1%)19 (1.6%)000 NR**5 (.1%)1 (.1%)2 (.2%)77 (86.5%)1 (.1%)002 (66.7%) Total6986 (100%)689 (100%)1165 (100%)89 (100%)1161 (100%)80 (100%)347 (100%)3 (100%) * Number of patients having C.V.V. HD not included. NR** - Not Reported ANZDATA Registry Annual Report 2012

13. Figure 5.12 ANZDATA Registry Annual Report 2012

14. Figure 5.13 ANZDATA Registry Annual Report 2012

15. Figure 5.14 Duration and Number of Sessions Per Week December 2011 Sessions Per week Hours of Each Treatment Total <444.555.5>5.5Not Reported Australia 3.1-4.942 (7.6%)78 (14.1%)46 (8.3%)126 (22.7%)17 (3.1%)245 (44.2%) 554 (100%) <=3361 (4.4%)3264 (40.2%)1807 (22.2%)2369 (29.1%)129 (1.6%)195 (2.4%)2 (0%)8127 (100%) >=570 (42.4%)43 (26.1%)3 (1.8%)5 (3%)1 (.6%)43 (26.1%) 165 (100%) Not reported 1 (1.2%) 82 (98.8%)83 (100%) Total473 (5.3%)3385 (37.9%)1856 (20.8%)2501 (28%)147 (1.6%)483 (5.4%)84 (.9%)8929 (100%) New Zealand 3.1-4.98 (4.7%)31 (18.3%)18 (10.7%)59 (34.9%)10 (5.9%)43 (25.4%) 169 (100%) <=320 (1.4%)455 (32.6%)346 (24.8%)473 (33.9%)34 (2.4%)67 (4.8%) 1395 (100%) >=59 (37.5%)7 (29.2%)2 (8.3%) 1 (4.2%)3 (12.5%) 24 (100%) Not reported 1 (33.3%) 2 (66.7%)3 (100%) Total37 (2.3%)493 (31%)366 (23%)535 (33.6%)45 (2.8%)113 (7.1%)2 (.1%)1591 (100%) * Intermediate durations are rounded up, e.g. 4.25 is included in 4.5 ANZDATA Registry Annual Report 2012

16. Figure 5.15 ANZDATA Registry Annual Report 2012

17. Figure 5.16 ANZDATA Registry Annual Report 2012

18. Figure 5.17 ANZDATA Registry Annual Report 2012

19. Figure 5.18 ANZDATA Registry Annual Report 2012

20. Figure 5.19 ANZDATA Registry Annual Report 2012

21. Figure 5.20 ANZDATA Registry Annual Report 2012

22. Figure 5.21 Haemodialysis Percentage ≥ 5 Sessions per Week By Australian State and Country Australia New Zealand QldNSW/ACTVicTasSANTWA Dec-1161 (3.7%)24 (.8%)50 (2.2%)2 (1.3%)7 (1.2%)3 (.7%)18 (2.1%)24 (1.5%) Dec-1052 (3.2%)25 (.9%)48 (2.2%)3 (2.1%)8 (1.4%)5 (1.2%)15 (1.9%)28 (1.8%) Dec-0941 (2.6%)28 (1%)40 (1.9%)2 (1.4%)7 (1.3%)-10 (1.3%)28 (1.9%) Dec-0851 (3.5%)25 (1%)46 (2.2%)2 (1.5%)10 (2%)1 (.3%)12 (1.6%)34 (2.5%) ANZDATA Registry Annual Report 2012

23. Figure 5.22 Haemodialysis Percentage ≥ 4.5 Hours Per Session Three Sessions per Week By Australian State and Country Australia New Zealand QldNSW/ACTVicTasSANTWA Dec-11840 (51.2%)1917 (65.9%)889 (38.6%)100 (63.3%)133 (22.2%)318 (72.6%)213 (24.3%)916 (57.6%) Dec-10829 (51.1%)1857 (65.9%)757 (34%)79 (54.1%)138 (24.5%)300 (74.8%)201 (25%)827 (53.4%) Dec-09788 (50.3%)1746 (64.5%)663 (31.2%)81 (54.7%)132 (24.4%)305 (79.6%)192 (24.7%)753 (50.9%) Dec-08727 (49.3%)1734 (66.1%)642 (30.9%)55 (41%)105 (21.4%)278 (76.8%)176 (22.9%)651 (48.5%) ANZDATA Registry Annual Report 2012

24. Figure 5.23 Haemodialysis Percentage >12 Hours per Week By Australian State and Country Australia New Zealand QldNSW/ACTVicTasSANTWA Dec-111006 (61.3%)2176 (74.8%)1087 (47.1%)112 (70.9%)160 (26.8%)328 (74.9%)272 (31%)1105 (69.5%) Dec-10996 (61.4%)2080 (73.8%)959 (43%)92 (63%)167 (29.6%)310 (77.3%)255 (31.7%)993 (64.1%) Dec-09964 (61.5%)1988 (73.4%)873 (41.1%)92 (62.2%)161 (29.8%)308 (80.4%)238 (30.7%)905 (61.1%) Dec-08893 (60.5%)1950 (74.4%)841 (40.5%)64 (47.8%)131 (26.7%)285 (78.7%)215 (28%)781 (58.2%) ANZDATA Registry Annual Report 2012

25. Figure 5.24 Haemodialysis at 90 Days Patient Survival Censored for Transplant 2000 - 2011 % [95% Confidence Interval] No. of Patients Survival 6 months1 year3 years5 years Australia 2000-2002314496 [96, 97]90 [89, 91]68 [67, 70]50 [48, 52] 2003-2005378396 [95, 97]90 [88, 90]67 [66, 69]48 [47, 50] 2006-2008445496 [95, 96]90 [89, 91]69 [67, 70]52 [50, 53] 2009-2011413796 [96, 97]91 [90, 92]-- New Zealand 2000-200256797 [95, 98]93 [90, 95]71 [67, 75]47 [42, 51] 2003-200565597 [95, 98]90 [88, 93]70 [66, 73]48 [44, 52] 2006-200869397 [95, 98]92 [89, 93]69 [65, 72]50 [45, 55] 2009-201173597 [96, 98]94 [92, 95]-- ANZDATA Registry Annual Report 2012

26. Figure 5.25 ANZDATA Registry Annual Report 2012

27. Figure 5.26 ANZDATA Registry Annual Report 2012

28. Figure 5.27 ANZDATA Registry Annual Report 2012

29. Figure 5.28 ANZDATA Registry Annual Report 2012

30. Figure 5.29 Haemodialysis at 90 Days Patient Survival - Diabetic / Non Diabetic Censored for Transplant 2000 - 2011 % [95% Confidence Interval] Survival No. of Patients 6 months1 year3 years5 years Australia Non Diabetic1054996 [96, 96]90 [89, 90]70 [69, 71]52 [51, 53] Diabetic496997 [96, 97]90 [89, 91]67 [65, 68]46 [44, 48] New Zealand Non Diabetic141497 [96, 98]92 [90, 93]74 [71, 76]54 [51, 58] Diabetic123697 [96, 98]92 [90, 94]68 [65, 70]43 [40, 47] ANZDATA Registry Annual Report 2012

31. Figure 5.30 ANZDATA Registry Annual Report 2012

32. Figure 5.31 ANZDATA Registry Annual Report 2012

33. Figure 5.32 Haemodialysis at 90 Days Patient Survival - By Age Group Censored for Transplant 2000 - 2011 % [95% Confidence Interval] Age Groups No. of Patients Survival 6 months1 year3 years5 years Australia 0-39 years159999 [99, 100]97 [96, 98]88 [86, 90]81 [78, 84] 40-59 years491098 [97, 98]94 [93, 95]80 [78, 81]66 [64, 68] 60-74 years553196 [95, 96]89 [88, 89]66 [64, 67]46 [45, 48] >=75 years347894 [93, 94]84 [83, 85]52 [50, 54]28 [27, 30] New Zealand 0-39 years361100 [98, 100]97 [95, 99]83 [77, 87]71 [64, 78] 40-59 years113097 [96, 98]94 [93, 95]79 [76, 82]57 [53, 60] 60-74 years93196 [95, 97]90 [88, 92]64 [60, 67]40 [36, 44] >=75 years22895 [91, 97]81 [76, 86]43 [35, 50]18 [12, 25] ANZDATA Registry Annual Report 2012

34. Figure 5.33 ANZDATA Registry Annual Report 2012

35. Figure 5.34 ANZDATA Registry Annual Report 2012

36. Figure 5.35 Haemodialyser Membrane Types by Surface Area 31-DEC-2011 Dialyser Membrane Type Flux Square Metres Total <1.01.0-1.41.5-1.71.8-1.9>1.9 Australia Cellulose TriacetateHigh..2114154 DiacetateLow....11 PolyamixHigh537665.22052912 PolyamixLow.625.2354 PolyethersulfoneHigh..3691100 PolynephronHigh....77 PolysulphoneHigh16.7216 PolysulphoneLow13.224369 Polysulphone-HelixoneHigh2591.329016805563 PolysynthaneLow....11 Total 9643695333641648847 New Zealand PolyamixHigh.349.440492 PolyamixLow.357.130190 PolysulphoneLow.1.79102182 Polysulphone-HelixoneHigh.363.26795725 Total.3701063467671589 ANZDATA Registry Annual Report 2012

37. Figure 5.36 Number of Patients at end of 2011 by HD Modality NTNSW/ACTVICQLDSAWATASNZTotal HAEMODIALYSIS-HOLLOW FIBRE DIALYSERS 42624992287138045968012312439097 HAEMOFILTRATION0000044311 HAEMODIAFILTRATION937919262139125313421306 Total 435289823061642598809158158810434 ANZDATA Registry Annual Report 2012

38. Figure 5.37 ANZDATA Registry Annual Report 2012

39. Figure 5.38 ANZDATA Registry Annual Report 2012

40. Figure 5.39 ANZDATA Registry Annual Report 2012

41. Figure 5.40 ANZDATA Registry Annual Report 2012

42. Figure 5.41 ANZDATA Registry Annual Report 2012

43. Figure 5.42 AUST ANZDATA Registry Annual Report 2012

44. Figure 5.42 NZ ANZDATA Registry Annual Report 2012

45. Figure 5.43 ANZDATA Registry Annual Report 2012

46. Figure 5.44 ANZDATA Registry Annual Report 2012

47. Figure 5.45 ANZDATA Registry Annual Report 2012

48. Figure 5.46 ANZDATA Registry Annual Report 2012

49. Figure 5.47 ANZDATA Registry Annual Report 2012

50. Figure 5.48 ANZDATA Registry Annual Report 2012

51. Figure 5.49 ANZDATA Registry Annual Report 2012

52. Figure 5.50 ANZDATA Registry Annual Report 2012

53. Figure 5.51 ANZDATA Registry Annual Report 2012

54. Figure 5.52 ANZDATA Registry Annual Report 2012

55. Figure 5.53 ANZDATA Registry Annual Report 2012

56. Figure 5.54 ANZDATA Registry Annual Report 2012

57. Figure 5.55 ANZDATA Registry Annual Report 2012

58. Figure 5.56 ANZDATA Registry Annual Report 2012

59. Figure 5.57 ANZDATA Registry Annual Report 2012

60. Figure 5.58 ANZDATA Registry Annual Report 2012

61. Figure 5.59 ANZDATA Registry Annual Report 2012

62. Figure 5.60 ANZDATA Registry Annual Report 2012

63. Figure 5.61 ANZDATA Registry Annual Report 2012

64. Figure 5.62 ANZDATA Registry Annual Report 2012

65. Figure 5.63 ANZDATA Registry Annual Report 2012

66. Figure 5.64 Urea Reduction Ratio - Prevalent Patients Three Sessions per Week - December 2011 Hours per Session Urea Reduction Ratio % < 65>=65Total Australia <4 hours 41 (13.4%)265 (86.6%)306 4 hours 266 (8.9%)2725 (91.1%)2991 >4-5 hours 282 (7.3%)3575 (92.7%)3857 >5 hours 23 (9.6%)217 (90.4%)240 Total 612 (8.3%)6782 (91.7%)7394 New Zealand <4 hours 8 (44.4%)10 (55.6%)18 4 hours 104 (26.0%)296 (74.0%)400 >4-5 hours 174 (24.0%)550 (76.0%)724 >5 hours 17 (20.7%)65 (79.3%)82 Total 303 (24.8%)921 (75.2%)1224 ANZDATA Registry Annual Report 2012

67. Figure 5.65 ANZDATA Registry Annual Report 2012

68. Figure 5.66 ANZDATA Registry Annual Report 2012

69. Figure 5.67 ANZDATA Registry Annual Report 2012

70. Figure 5.68 ANZDATA Registry Annual Report 2012

71. Figure 5.69 ANZDATA Registry Annual Report 2012

72. Figure 5.70 ANZDATA Registry Annual Report 2012

73. Figure 5.71 ANZDATA Registry Annual Report 2012

74. Figure 5.72 ANZDATA Registry Annual Report 2012

75. Figure 5.73 ANZDATA Registry Annual Report 2012

76. Figure 5.74 ANZDATA Registry Annual Report 2012

77. Figure 5.75 ANZDATA Registry Annual Report 2012

78. Figure 5.76 ANZDATA Registry Annual Report 2012

79. Figure 5.77 ANZDATA Registry Annual Report 2012

80. Figure 5.78 ANZDATA Registry Annual Report 2012

81. Figure 5.79 Vascular Access at First Treatment Haemodialysis as Initial Modality 1-Jan-2008 to 31-Dec-2011 2008200920102011 AVF or AVGCVCAVF or AVGCVCAVF or AVGCVCAVF or AVGCVC Australia QLD 139 (36%)250 (64%)152 (41%)219 (59%)138 (40%)207 (60%)131 (40%)197 (60%) NSW/ACT 189 (34%)374 (66%)185 (37%)316 (63%)200 (37%)339 (63%)223 (39%)347 (61%) Vic 185 (47%)212 (53%)214 (50%)216 (50%)200 (45%)246 (55%)230 (51%)223 (49%) Tas 12 (35%)22 (65%)16 (43%)21 (57%)19 (61%)12 (39%)19 (61%)12 (39%) SA 70 (53%)61 (47%)89 (61%)58 (39%)55 (40%)82 (60%)91 (68%)42 (32%) NT 39 (49%)41 (51%)27 (46%)32 (54%)25 (45%)30 (55%)38 (49%)40 (51%) WA 67 (34%)131 (66%)66 (38%)106 (62%)52 (31%)114 (69%)86 (41%)124 (59%) New Zealand 73 (23%)247 (77%)111 (31%)249 (69%)83 (25%)250 (75%)93 (30%)220 (70%) ANZDATA Registry Annual Report 2012

82. Figure 5.80 ANZDATA Registry Annual Report 2012

83. Figure 5.81 ANZDATA Registry Annual Report 2012

84. Figure 5.82 ANZDATA Registry Annual Report 2012

85. Figure 5.83 ANZDATA Registry Annual Report 2012

86. Figure 5.84 ANZDATA Registry Annual Report 2012

87. Figure 5.85 ANZDATA Registry Annual Report 2012

88. Figure 5.86 ANZDATA Registry Annual Report 2012

89. Figure 5.87 ANZDATA Registry Annual Report 2012

90. Figure 5.88 ANZDATA Registry Annual Report 2012

91. Figure 5.89 ANZDATA Registry Annual Report 2012

92. Figure 5.90 ANZDATA Registry Annual Report 2012

93. Figure 5.91 Prevalent Vascular Access at 31-Dec-2011 Dec 2008Dec 2009Dec 2010Dec 2011 AVF or AVGCVCAVF or AVGCVCAVF or AVGCVCAVF or AVGCVC Australia QLD 1283 (87%)192 (13%)1372 (88%)196 (13%)1426 (88%)196 (12%)1429 (87%)212 (13%) NSW/ACT 2200 (84%)421 (16%)2259 (83%)449 (17%)2387 (85%)430 (15%)2479 (86%)415 (14%) Vic 1860 (90%)215 (10%)1899 (89%)227 (11%)1972 (88%)257 (12%)2049 (89%)256 (11%) Tas 110 (82%)24 (18%)118 (80%)30 (20%)128 (88%)18 (12%)134 (85%)24 (15%) SA 429 (88%)61 (12%)484 (90%)56 (10%)504 (89%)60 (11%)556 (93%)42 (7%) NT 328 (91%)34 (9%)366 (96%)17 (4%)367 (92%)34 (8%)394 (90%)42 (10%) WA 562 (73%)205 (27%)593 (76%)183 (24%)619 (78%)179 (22%)634 (78%)174 (22%) New Zealand 983 (73%)360 (27%)1111 (75%)369 (25%)1204 (78%)345 (22%)1241 (78%)347 (22%) ANZDATA Registry Annual Report 2012

94. Figure 5.92 ANZDATA Registry Annual Report 2012

95. Figure 5.93 ANZDATA Registry Annual Report 2012

96. Figure 5.94 ANZDATA Registry Annual Report 2012

97. Figure 5.95 ANZDATA Registry Annual Report 2012

98. Figure 5.96 ANZDATA Registry Annual Report 2012

99. Figure 5.97 ANZDATA Registry Annual Report 2012

100. Figure 5.98 ANZDATA Registry Annual Report 2012

101. Figure 5.99 ANZDATA Registry Annual Report 2012

102. Figure 5.100 ANZDATA Registry Annual Report 2012

103. Figure 5.101 ANZDATA Registry Annual Report 2012

104. Figure 5.102 ANZDATA Registry Annual Report 2012

105. Figure 5.103 ANZDATA Registry Annual Report 2012

106. Figure 5.104 ANZDATA Registry Annual Report 2012

107. Figure 5.105 ANZDATA Registry Annual Report 2012

108. Figure 5.106 ANZDATA Registry Annual Report 2012

109. The distribution of prevalent home dialysis patients by age group is shown in Figure 5.107. Figure 5.107 ANZDATA Registry Annual Report 2012

110. Figure 5.108 Proportion (%) of Prevalent Patients aged ≥ 65 years Treated with Home Haemodialysis 2007 - 2011 State 20072008200920102011 Australia Queensland5.40%5.50%5.40%5.10%4.90% New South Wales/ACT9.00%8.30%8.10%7.70%7.40% Victoria4.90%4.70%4.40%4.00%3.80% Tasmania2.10%2.50%2.80%3.30%2.60% South Australia0.50%0.60%0.70%0.90%1.10% Northern Territory3.70%4.30%5.60%5.30%5.00% Western Australia1.50% 1.90%2.50%2.60% New Zealand 9.60%9.50%10.30%11.10%11.20% ANZDATA Registry Annual Report 2012

111. Figure 5.109 ANZDATA Registry Annual Report 2012

112. Figure 5.110 ANZDATA Registry Annual Report 2012

113. Figure 5.111 ANZDATA Registry Annual Report 2012

114. Figure 5.112 ANZDATA Registry Annual Report 2012

115. Figure 5.113 ANZDATA Registry Annual Report 2012

116. Definitions in use CARI guidelinesCaring for Australasians with Renal Impairment guidelines Quotidian HD> 3 sessions/week and/or > 5.5 hours/session Long Hour HD= 6.5 hours per HD session High Flux DialyserUltrafiltration coefficient (kuf) >20 ml/hr/mmHg as specified by the manufacturer) AVFNative vein arteriovenous fistula AVGSynthetic arteriovenous bridge graft CVCCentral venous HD catheter (Includes both tunnelled and non-tunnelled unless otherwise stated) Obese BMI = 30 Morbid Obesity BMI = 35 ANZDATA Registry Annual Report 2012